603 related articles for article (PubMed ID: 27756478)
1. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
Toth PP; Catapano AL; Farnier M; Foody J; Tomassini JE; Jensen E; Polis AB; Hanson ME; Musliner TA; Tershakovec AM
Am J Cardiol; 2016 Dec; 118(12):1812-1820. PubMed ID: 27756478
[TBL] [Abstract][Full Text] [Related]
2. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
3. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
[TBL] [Abstract][Full Text] [Related]
4. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B
Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192
[TBL] [Abstract][Full Text] [Related]
5. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
Descamps O; Tomassini JE; Lin J; Polis AB; Shah A; Brudi P; Hanson ME; Tershakovec AM
Atherosclerosis; 2015 Jun; 240(2):482-9. PubMed ID: 25913444
[TBL] [Abstract][Full Text] [Related]
6. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
7. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
9. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Rosen JB; Ballantyne CM; Hsueh WA; Lin J; Shah AK; Lowe RS; Tershakovec AM
Lipids Health Dis; 2015 Sep; 14():103. PubMed ID: 26336957
[TBL] [Abstract][Full Text] [Related]
10. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P
J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523
[TBL] [Abstract][Full Text] [Related]
11. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
[TBL] [Abstract][Full Text] [Related]
13. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
[TBL] [Abstract][Full Text] [Related]
14. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.
Derosa G; D'Angelo A; Franzetti IG; Ragonesi PD; Gadaleta G; Scalise F; Ciccarelli L; Piccinni MN; Cicero AF
J Clin Pharm Ther; 2009 Jun; 34(3):267-76. PubMed ID: 19650249
[TBL] [Abstract][Full Text] [Related]
16. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
17. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
18. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
Miyoshi T; Nakamura K; Doi M; Ito H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
[TBL] [Abstract][Full Text] [Related]
19. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]